A National Registry on Chinese Patients With Cystic Fibrosis

Last updated: March 13, 2022
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cystic Fibrosis

Lung Disease

Treatment

N/A

Clinical Study ID

NCT05289245
XT 02
  • All Genders

Study Summary

Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Eligibility Criteria

Inclusion

Inclusion Criteria: Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with norespiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informedconsent.

Exclusion

Exclusion Criteria: Patients with other bronchiectasis who did not meet the inclusion criteria; Those withsevere cardiac or renal disease

Study Design

Total Participants: 200
Study Start date:
April 01, 2022
Estimated Completion Date:
October 01, 2032

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.